diabetestalk.net

Insulin Resistance Treatment

Share on facebook

Treatment Of Obese Insulin-resistant Mice With An Allosteric Mapkapk2/3 Inhibitor Lowers Blood Glucose And Improves Insulin Sensitivity

The prevalence of obesity-induced type 2 diabetes (T2D) is increasing worldwide, and new treatment strategies are needed. We recently discovered that obesity activates a previously unknown pathway that promotes both excessive hepatic glucose production (HGP) and defective insulin signaling in hepatocytes, leading to exacerbation of hyperglycemia and insulin resistance in obesity. At the hub of this new pathway is a kinase cascade involving calcium/calmodulin-dependent protein kinase II (CaMKII), p38α mitogen-activated protein kinase (MAPK), and MAPKAPK2/3 (MK2/3). Genetic-based inhibition of these kinases improves metabolism in obese mice. Here, we report that treatment of obese insulin-resistant mice with an allosteric MK2/3 inhibitor, compound (cmpd) 28, ameliorates glucose homeostasis by suppressing excessive HGP and enhancing insulin signaling. The metabolic improvement seen with cmpd 28 is additive with the leading T2D drug, metformin, but it is not additive with dominant-negative MK2, suggesting an on-target mechanism of action. Allosteric MK2/3 inhibitors represent a potentially new approach to T2D that is highly mechanism based, has links to human T2D, and is predicted to Continue reading >>

Share on facebook

Popular Questions

  1. JM97

    For this reason "insulin insensitivity", or a decrease in insulin receptor signaling, leads to diabetes mellitus type 2 – the cells are unable to take up glucose, and the result is hyperglycemia (an increase in circulating glucose), and all the sequelae that result from diabetes


    (1)
    (1)
    Also
    Type 2 diabetes is due to insufficient insulin production from beta cells in the setting of insulin resistance.


    (2)
    (2)
    So why don't we give people a medicine which just increases the number of receptors or increases the sensitivity of receptors? Isn't it illogical to give more of insulin for a deficit amount of receptors? So, what is the logic behind giving insulin?

  2. another 'Homo sapien'

    Isn't it illogical to give more of insulin for a deficit amount of receptors?
    Seems like there is some confusion in the definition of type-2 DM itself. According to the American Diabetes Association:
    If you have type 2 diabetes your body does not use insulin properly. This is called insulin resistance. At first, your pancreas makes extra insulin to make up for it. But, over time it isn't able to keep up and can't make enough insulin to keep your blood glucose at normal levels.
    So the problem in type-1 DM and type-2 DM is quite same; both because of less insulin present than required, the difference being that in type-2 DM the cells need more insulin than normal. And that apparent deficiency of insulin is overcome by insulin injections. Also, the definition you cite doesn't say receptor deficiency anywhere, it just says decrease in receptor's response to insulin.
    So why don't we give people a medicine which just increases the number of receptors or increases the sensitivity of receptors?
    This is not quite possible yet. Increasing the number of receptors means increasing the gene expression for that receptor, something that is called 'upregulation'. Now, just to add, the cause of type-2 DM has been regarded to be downregulation of insulin receptors on cell surface by high concentration of insulin. See this article:
    The process of downregulation occurs when there are elevated levels of the hormone insulin in the blood. When insulin binds to its receptors on the surface of a cell, the hormone receptor complex undergoes endocytosis and is subsequently attacked by intracellular lysosomal enzymes. The internalization of the insulin molecules provides a pathway for degradation of the hormone as well as for regulation of the number of sites that are available for binding on the cell surface. At high plasma concentrations, the number of surface receptors for insulin is gradually reduced by the accelerated rate of receptor internalization and degradation brought about by increased hormonal binding. The rate of synthesis of new receptors within the endoplasmic reticulum and their insertion in the plasma membrane do not keep pace with their rate of destruction. Over time, this self-induced loss of target cell receptors for insulin reduces the target cell's sensitivity to the elevated hormone concentration.
    Now, coming back to the main point, it is not yet possible to inject transcription factors in every cell of body so that more and more receptors can be produced. It is possible in vitro, but not in vivo yet. However, it is possible to inject something else instead of insulin which might have similar effects on the body, something known as insulin agonist. Researchers are already trying to create insulin agonists, but haven't achieved much success. See this paper for example, in which they talk about a peptide S961. The problem here is that most of the molecules synthesized act as both agonist and antagonist based on different concentrations. That is why this field has not seen much success.
    EDIT: As mentioned by @Don_S in comments, some drugs reportedly do increase insulin sensitivity and number of receptors in cells. Though they have indirect mechanisms for this, unlike insulin itself, but this works too (at least in vitro). One of them, thiazolidinediones, activates a nuclear receptor PPAR

    γ
    γ, which in turn increases transcription of proteins involved in glucose and lipid metabolism and energy balance. Another drug, pioglitazone, works even in vivo and has been suggested to work by activating receptor kinases and thus increase insulin sensitivity.
    Thus, in future, it is very likely that type-2 DM patients would get prescriptions of such drugs instead of insulin injections, but not until there are more such drugs available and at an affordable cost.
    References:

    Type 2 — American Diabetes Association

    Downregulation and upregulation — Wikipedia

    Knudsen L, Hansen BF, Jensen P, Pedersen TÅ, Vestergaard K, Schäffer L, et al. (2012) Agonism and Antagonism at the Insulin Receptor. PLoS ONE 7(12): e51972. doi:10.1371/journal.pone.0051972

    Hauner H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 2002;18(Suppl. 2):S10–S15. doi: 10.1002/dmrr.249.

    Kobayashi, M, Iwanishi, M, Egawa, K et al, Pioglitazone increases insulin sensitivity by activating kinase of insulin receptors. Diabetes. 1992;41:476–483.

  3. Chris

    This is true for the beginning of the disease. As a reaction to the reduced sensitivity of the cells in the body to insulin (and thus less uptake of glucose from the blood and a resulting hyperglycemia) the body produces more and more insulin to cope with this problem.
    At some point the insulin producing beta cells cannot increase the production anymore and due to the insulin resistance this amount is not enough anymore. At this point insulin needs to be supplied to the body to ensure normal function and to combat hyperglycemia. See this figure for a schematic overview (from here):
    For more details see this paper:
    Defining and Characterizing the Progression of Type 2 Diabetes

  4. -> Continue reading
read more close

Related Articles

  • Insulin Resistance Treatment Metformin

    If type 2 diabetes is part of your life—whether you have the condition or are at risk of developing it—you’ve probably heard of a drug called metformin. Perhaps your doctor has told you about it, has recently started you on it or has been prescribing it to you for years to keep your blood sugar under control. It’s no newbie. Metformin has been available by prescription in the US for more than 20 years and in Europe for more than 40 years. ...

    insulin Mar 13, 2018
  • Treatment For Insulin Resistance

    Understanding the cellular mechanisms of insulin resistance helps us choose more effective therapeutic interventions for the treatment and prevention of prediabetes and type 2 diabetes. Insulin resistance is present in individuals who are obese and those with diabetes mellitus. Several studies have found that an insulin resistance diet protocol and exercise can alter insulin signaling pathways and delay the onset of insulin resistance. It’s est ...

    insulin Mar 31, 2018
  • Insulin Resistance Pcos Natural Treatment

    Want to cure your polycystic ovarian syndrome fast and finally fall pregnant? Then here's 9 natural treatments and home remedies you definitely must consider... I have PCOS and it's making my life hell. I would also like to have a child but cannot fall pregnant. Do you have any helpful advice? Thank you. ANSWER: Polycystic ovarian syndrome (PCOS) is a common condition that affects anywhere from 5-20% of women at childbearing age and is the #1 cau ...

    insulin Apr 24, 2018
  • Insulin Resistance Hypoglycemia Treatment

    Insulin resistance is a characteristic of type 2 diabetes, but not everyone who has insulin resistance (IR) will develop diabetes. It is usually genetic in origin and tends to run in families. Other factors that can contribute to developing insulin resistance include: inactivity, poor dietary habits, and excess weight gain (which came first –IR or the weight?). Insulin resistance basically means that the body is making poor quality insulin and ...

    insulin Dec 30, 2017
  • Insulin Resistance Treatment

    Tweet Insulin resistance is the name given to when cells of the body don’t respond properly to the hormone insulin. Insulin resistance is the driving factor that leads to type 2 diabetes, gestational diabetes and prediabetes. Insulin resistance is closely associated with obesity; however, it is possible to be insulin resistant without being overweight or obese. Modern research has shown that insulin resistance can be combatted by treatment meth ...

    insulin Apr 16, 2018
  • Insulin Resistance In Type 1 Diabetes Treatment

    Go to: Double diabetes The term ‘double diabetes’ was first coined in 1991 based on the observation that patients with type 1 diabetes who had a family history of type 2 diabetes were more likely to be overweight and rarely achieved adequate glycaemic control even with higher insulin doses [1]. The more extensive, or stronger, the family history, the higher the dose the patient received. The authors suggested that this might indicate the pres ...

    diabetes Apr 14, 2018

Popular Articles

More in insulin